Main Stories

Editor’s Picks

Trending Stories

New Therapeutic Option to Reduce Risk of Cardiovascular Deaths and Repeated Hospitalisations Among Adult Heart Failure Patients Approved in Singapore

Bayer's VERQUVO™ (vericiguat), a soluble guanylate cyclase (sGC) stimulator, has been approved in Singapore for the treatment of symptomatic chronic...

Brii Bio Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron BA.2 Subvariant

Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK), a multi-national company developing innovative therapies for diseases with...